Description
Buy Authentic Cagrilintide 5mg online
Cagrilintide 5mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
What Cagrilintide 5mg is
Cagrilintide is an investigational long-acting amylin analog. It’s also known as NN9838 and was developed by Novo Nordisk. The “5mg” refers to lyophilized powder per vial for research use. Amylin is a hormone co-secreted with insulin that helps regulate satiety, gastric emptying, and glucose. Cagrilintide is modified for a long half-life to study sustained amylin receptor activation. It is not FDA-approved and is sold strictly as a research chemical.
Key Product Details Of Cagrilintide 5mg
- Manufactured in accordance with rigorous quality standards to support ≥99% purity, as reflected in batch-specific documentation where available.
- Every batch is third-party analyzed for identity, assay/potency, and sterility documentation where applicable.
- Supplied in lyophilized powder form to help preserve stability throughout transport and storage.
- Produced with lot-level traceability to support research documentation and laboratory recordkeeping.
Research Documentation Context
- Supports compound characterization in controlled laboratory settings.
- Provides batch-specific identity and purity documentation for research review.
- Allows lot-level traceability across laboratory documentation workflows.
- Supports comparison of product labeling, analytical documentation, and storage information during research planning.
- Supports analytical review of receptor-pathway research materials within a strictly laboratory-focused context.
Specifications and Documentation
- Certificate of Analysis: Available with batch-specific documentation where applicable.
- Material Safety Data Sheet: Coming Soon.
- Handling and Storage Instructions: Coming Soon.
- Product Form: Lyophilized powder.
- Purity Specification: ≥99% purity.
- Intended Use: Laboratory research use only.
Cagrilintide 5mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
How researchers study it
In preclinical and clinical models, Cagrilintide is used to investigate appetite regulation, body weight, and glucose control. Amylin agonism slows gastric emptying and signals fullness to the brain, mainly via the area postrema. Researchers combine it with GLP-1R agonists like semaglutide to test if dual incretin + amylin pathways give additive weight loss. Endpoints in studies include body weight, food intake, HbA1c, and safety/tolerability.
Why it got research attention
Interest grew after Phase 1 and Phase 2 trials testing Cagrilintide + semaglutide, called “CagriSema.” The combination showed greater weight loss than semaglutide alone in obesity and T2D trials. The idea is that GLP-1 handles glucose and satiety while amylin adds another layer of appetite suppression and gastric slowing. It’s part of the broader push for multi-pathway metabolic drugs alongside GLP-1/GIP/GCGR peptides.
Form, purity & handling
Cagrilintide 5mg for research typically comes as a white, freeze-dried powder in a sterile vial. Reputable suppliers should provide a COA with HPLC and mass spec confirming peptide sequence and purity, usually >95% for research grade. Peptides degrade with heat, light, and moisture. Store at -20°C or -80°C after reconstitution. The clinical trial drug product is a separate, GMP formulation and not commercially available
Legal + safety status
Cagrilintide is not FDA-approved for any indication. It’s labeled “for research use only, not for human consumption.” It remains in clinical development by Novo Nordisk. There is no established human dosing outside trials, no long-term safety data, and no proven clinical benefit yet. In trials, amylin analogs have reported GI effects similar to GLP-1 drugs, plus potential nausea. It’s not approved for medical use and cannot be prescribed.
Bottom line
*Cagrilintide 5mg* is an investigational research peptide used to study long-acting amylin agonism for obesity and metabolic disease. Early trial data with CagriSema showed promising weight loss, but the compound has no regulatory approval. *No peptide is a substitute for FDA-approved therapies or evidence-based medical care.* For weight, diabetes, or metabolic health concerns, talk to a licensed healthcare provider about approved GLP-1 drugs, lifestyle interventions, and therapies with proven clinical data.
